Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F.
FL-HN
VAMP2
botulinum neurotoxin
functional molecule
immunological characterization
neurotoxicity
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
06 03 2023
06 03 2023
Historique:
received:
05
02
2023
revised:
02
03
2023
accepted:
03
03
2023
medline:
30
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Botulinum neurotoxins (BoNTs) can cause nerve paralysis syndrome in mammals and other vertebrates. BoNTs are the most toxic biotoxins known and are classified as Class A biological warfare agents. BoNTs are mainly divided into seven serotypes A-G and new neurotoxins BoNT/H and BoNT/X, which have similar functions. BoNT proteins are 150 kDa polypeptide consisting of two chains and three domains: the light chain (L, catalytic domain, 50 kDa) and the heavy chain (H, 100 kDa), which can be divided into an N-terminal membrane translocation domain (HN, 50 kDa) and a C-terminal receptor binding domain (Hc, 50 kDa). In current study, we explored the immunoprotective efficacy of each functional molecule of BoNT/F and the biological characteristics of the light chain-heavy N-terminal domain (FL-HN). The two structure forms of FL-HN (i.e., FL-HN-SC: single chain FL-HN and FL-HN-DC: di-chain FL-HN) were developed and identified. FL-HN-SC could cleave the vesicle associated membrane protein 2 (VAMP2) substrate protein in vitro as FL-HN-DC or FL. While only FL-HN-DC had neurotoxicity and could enter neuro-2a cells to cleave VAMP2. Our results showed that the FL-HN-SC had a better immune protection effect than the Hc of BoNT/F (FHc), which indicated that L-HN-SC, as an antigen, provided the strongest protective effects against BoNT/F among all the tested functional molecules. Further in-depth research on the different molecular forms of FL-HN suggested that there were some important antibody epitopes at the L-HN junction of BoNT/F. Thus, FL-HN-SC could be used as a subunit vaccine to replace the FHc subunit vaccine and/or toxoid vaccine, and to develop antibody immune molecules targeting L and HN domains rather than the FHc domain. FL-HN-DC could be used as a new functional molecule to evaluate and explore the structure and activity of toxin molecules. Further exploration of the biological activity and molecular mechanism of the functional FL-HN or BoNT/F is warranted.
Identifiants
pubmed: 36977091
pii: toxins15030200
doi: 10.3390/toxins15030200
pmc: PMC10056376
pii:
doi:
Substances chimiques
botulinum toxin type F
U1R2P71O7G
Botulinum Toxins, Type A
EC 3.4.24.69
Vesicle-Associated Membrane Protein 2
0
Neurotoxins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Hum Vaccin Immunother. 2020;16(1):100-108
pubmed: 31210561
Infect Immun. 2009 Jul;77(7):2795-801
pubmed: 19398544
Toxicon. 2020 Mar;176:67-76
pubmed: 32032587
Clin Vaccine Immunol. 2008 Dec;15(12):1819-23
pubmed: 18845829
Toxins (Basel). 2019 Nov 22;11(12):
pubmed: 31771110
Toxins (Basel). 2022 Feb 11;14(2):
pubmed: 35202162
Expert Rev Vaccines. 2013 May;12(5):481-92
pubmed: 23659297
Toxins (Basel). 2021 Dec 27;14(1):
pubmed: 35050996
Vaccine. 2020 Mar 23;38(14):2978-2983
pubmed: 32113807
Biochim Biophys Acta. 2016 Dec;1864(12):1678-1685
pubmed: 27596061
Vaccine. 2018 Feb 1;36(6):827-832
pubmed: 29307477
Microbiol Immunol. 2020 Jul;64(7):502-511
pubmed: 32301520
PLoS Pathog. 2022 Jan 6;18(1):e1010169
pubmed: 34990480
Toxins (Basel). 2021 Sep 10;13(9):
pubmed: 34564645
Pharmacol Rev. 2017 Apr;69(2):200-235
pubmed: 28356439
Protein Expr Purif. 2018 Jun;146:51-60
pubmed: 29407166
J Struct Biol. 2011 Apr;174(1):52-7
pubmed: 21078393
Toxins (Basel). 2018 Nov 26;10(12):
pubmed: 30486254
Biochem J. 2011 Jan 15;433(2):277-84
pubmed: 21029044
Toxins (Basel). 2021 Nov 24;13(12):
pubmed: 34941672
Annu Rev Biochem. 2019 Jun 20;88:811-837
pubmed: 30388027
Toxins (Basel). 2019 Sep 12;11(9):
pubmed: 31547338
Int J Mol Sci. 2021 Aug 09;22(16):
pubmed: 34445283
Vaccine. 2018 Apr 5;36(15):2041-2048
pubmed: 29475762
Toxins (Basel). 2019 Jan 11;11(1):
pubmed: 30641949
PLoS One. 2017 Mar 21;12(3):e0174187
pubmed: 28323873
Toxins (Basel). 2018 Jul 04;10(7):
pubmed: 29973505
Crit Rev Immunol. 2007;27(4):319-41
pubmed: 18197812
Nat Struct Mol Biol. 2009 Jul;16(7):789-94
pubmed: 19543288
Infect Immun. 2015 Apr;83(4):1465-76
pubmed: 25624352
Infect Immun. 2005 Oct;73(10):6998-7005
pubmed: 16177380
Hybridoma (Larchmt). 2012 Aug;31(4):233-9
pubmed: 22894775
Toxins (Basel). 2021 Oct 22;13(11):
pubmed: 34822535
Toxins (Basel). 2019 Jul 17;11(7):
pubmed: 31319550
Hum Vaccin Immunother. 2019;15(3):755-760
pubmed: 30433836
MMWR Morb Mortal Wkly Rep. 2011 Oct 28;60(42):1454-5
pubmed: 22031218
Toxins (Basel). 2018 Mar 01;10(3):
pubmed: 29494481
Toxins (Basel). 2020 Aug 07;12(8):
pubmed: 32784744
Semin Neurol. 2016 Feb;36(1):10-9
pubmed: 26866491
Toxicon. 2020 Apr 30;178:20-32
pubmed: 32094099
Toxins (Basel). 2018 May 10;10(5):
pubmed: 29748471
J Infect Dis. 2016 May 15;213(10):1606-14
pubmed: 26936913
Hum Vaccin Immunother. 2022 Nov 30;18(5):2048621
pubmed: 35435814
Toxins (Basel). 2017 Jan 18;9(1):
pubmed: 28106761
Toxins (Basel). 2021 Jan 14;13(1):
pubmed: 33466571
Protein Eng Des Sel. 2011 Mar;24(3):321-31
pubmed: 21149386
Infect Immun. 2008 Mar;76(3):1314-8
pubmed: 18070903
Toxins (Basel). 2020 Sep 24;12(10):
pubmed: 32987745
Toxins (Basel). 2017 Sep 02;9(9):
pubmed: 28869493
Toxins (Basel). 2018 Jul 02;10(7):
pubmed: 30004421
Crit Rev Immunol. 2010;30(2):167-87
pubmed: 20370628
Sci Rep. 2015 Oct 28;5:15776
pubmed: 26508475
Neurotox Res. 2021 Aug;39(4):1044-1053
pubmed: 33616873
Clin Immunol. 2010 Nov;137(2):271-80
pubmed: 20696619
Res Microbiol. 2015 May;166(4):290-302
pubmed: 25312020
Microorganisms. 2021 Oct 23;9(11):
pubmed: 34835332
Nat Rev Microbiol. 2014 Aug;12(8):535-49
pubmed: 24975322
Handb Exp Pharmacol. 2021;263:11-33
pubmed: 31792680